Evrofarma S.A.'s receivables is $10M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for EVROF.AT is $10M as of June 2026. That compares with $10M in the prior-year period — down 1.0% year over year. Investors often review this figure alongside Evrofarma S.A.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, EVROF.AT's receivables moved from $10M to $10M — a 1.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evrofarma S.A.'s operating scale or balance-sheet position.
A receivables figure of $10M for EVROF.AT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting EVROF.AT's receivables ($10M), review year-over-year change from $10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.